Cleveland Clinic

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Retrieved on:

星期三, 四月 17, 2024

Equity, Research, Cleveland Clinic, Doctor of Philosophy, Gastroparesis, KOL, Senior, Incidence, Metoclopramide, Research fellow

SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m.

Key Points:

SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m.
ET.
Moderated by Yale Jen, PhD, Senior Managing Director of Equity Research at Laidlaw Capital Markets, the event will feature Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic and prescriber of GIMOTI will provide his expert opinion and insights on Evoke’s recently presented healthcare resource utilization data, patient experience with GIMOTI and the rising incidence of gastroparesis due to the increased use GLP-1 based medications.

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Retrieved on:

星期二, 四月 16, 2024

Osteoarthritis, Economics, TELO, Hematology, Animal, Cleveland Clinic, Research, IND, Weakness, DRS, Medicine, Press club, Ageing, Longevity, Pharmaceutical industry

WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.

Key Points:

As part of its commitment to transparency and openness in sharing its research data, during the event, Drs.
Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres.
The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.
“Our National Press Club event was our first opportunity to share on a national stage Telomir-1’s potential to combat the diseases of aging,” stated Dr. Chapman.

Naples Soap Company to Launch New Sensitive Skincare Line for High Demand $41 Billion Market

Retrieved on:

星期二, 四月 30, 2024

The Grow Beautii line is set to serve an unmet segment of the rapidly growing $41 billion global sensitive skin care products market.

Key Points:

The Grow Beautii line is set to serve an unmet segment of the rapidly growing $41 billion global sensitive skin care products market.
View the full release here: https://www.businesswire.com/news/home/20240430706613/en/
Grow Beautii, a new line of skin care products formulated and designed specifically for users with sensitive skin is slated to launch in the fourth quarter of 2024.
“Creating self care and beauty products for sensitive skin is in our DNA at Naples Soap Company.
This personal journey is what inspired me to create and grow my own skin care line,” said Deanna Wallin, Founder & CEO of Naples Soap Company.

Executive War College to Address, Clinical Laboratories’ and Genetic Testing Firms’ Perfect Storm, involving FDA’s Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations

Retrieved on:

星期五, 四月 19, 2024

One is the Food and Drug Administration’s (FDA) proposed rule https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-ai... to regulate laboratory developed tests (LDTs).

Key Points:

One is the Food and Drug Administration’s (FDA) proposed rule https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-ai... to regulate laboratory developed tests (LDTs).
The third is a major rewrite and update to the CLIA regulations to which all labs must comply.
“Our expert content is what differentiates the Executive War College and provides true value to our attendees,” Michel said.
To register and for more information on Executive War College 2024, visit http://www.executivewarcollege.com .

Dermatology and Laser Center of Charleston Joins Epiphany Dermatology

Retrieved on:

星期一, 四月 22, 2024

Alternative Medicine, Surgery, General Health, Health, Consumer, Cosmetics, Other Consumer, Other Health, Medical school, Biomedical sciences, State university system, Partnership, Skin care, Entrepreneurship, Patient, Cleveland Clinic, Marketing, SUNY

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in South Carolina through its partnership with Todd Schlesinger, MD, and his team at Dermatology and Laser Center of Charleston, based in Charleston, South Carolina.

Key Points:

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in South Carolina through its partnership with Todd Schlesinger, MD, and his team at Dermatology and Laser Center of Charleston, based in Charleston, South Carolina.
Founded in 2005 by Dr. Schlesinger, Dermatology and Laser Center of Charleston has a solid reputation of providing high-quality dermatology and cosmetic services to patients in Charleston, SC, and surrounding communities.
I look forward to helping Epiphany maintain its high standards of quality patient care.”
Gheorghe Pusta, Co-Founder and Chief Executive Officer of Epiphany said, “We are excited to welcome Dr. Schlesinger and his team to Epiphany.
Epiphany also benefits from the clinical expertise of Dermatology and Laser Center of Charleston’s team, as best practices are collaboratively shared across the Epiphany network.

AMPEL BioSolutions Selected as Member of ARPA-H Customer Experience Hub Spoke Network

Retrieved on:

星期二, 四月 23, 2024

CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .

Key Points:

CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .
AMPEL's ARPA-H spoke election highlights one-of-a-kind Precision Health tests that predict inflammation and abnormal drug targets from gene expression utilizing "explainable AI" (xAI).
Other corporate Hub Spoke members include Verily, Datavant, Velsara, QuidelOrtho and Biolabs.
As a Customer Experience spoke, AMPEL has access to funding and flexible contracting for expeditious product execution and scaling.

Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems

Retrieved on:

星期一, 四月 22, 2024

FDA, Physics, Food, Cleveland Clinic, Vascular disease, ICE, Doctor of Philosophy, Moyamoya disease, Patient, Physician, Circulatory system, Expanse, Angiology, Thrombectomy, Growth, Medical device

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.

Key Points:

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.
The ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies.
"The thrombectomy market is witnessing robust growth and the approval of the ICE system comes at an auspicious time.

Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance for vessels of the peripheral arterial and venous systems

Retrieved on:

星期一, 四月 22, 2024

Physics, Food, Cleveland Clinic, Vascular disease, ICE, Doctor of Philosophy, Moyamoya disease, Patient, Physician, Circulatory system, Expanse, Angiology, Thrombectomy, Growth

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.

Key Points:

PLEASANTON, Calif., April 22, 2024 /PRNewswire/ -- Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food and Drug Administration.
The ICE System is specifically designed to address the complex challenges associated with peripheral thrombectomies.
Eitan Konstantino, PhD, a serial entrepreneur in the vascular device field, is the driving force behind Expanse ICE.
"The thrombectomy market is witnessing robust growth and the approval of the ICE system comes at an auspicious time.

ImpediMed to Present Chronic Breast Cancer-related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Retrieved on:

星期四, 四月 11, 2024

FDA, Cancer, American Cancer Society, Risk, Woman, Cleveland Clinic, Lymphedema, Research, Body composition, BIS, Patient, Society, Melanoma, MBA, Quality of life, Breast cancer, Medical imaging

CARLSBAD, Calif., April 11, 2024 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.

Key Points:

CARLSBAD, Calif., April 11, 2024 /PRNewswire/ -- ImpediMed , a leader in medical technologies to clinically monitor and manage fluid and body composition, announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.
"Chronic breast cancer-related lymphedema can represent a risk to patients who have undergone breast cancer treatment with meaningful impact on their quality of life," said Chirag Shah, MD, Co-Director of the Comprehensive Breast Cancer Program, Cleveland Clinic, lead author of the study, and scientific adviser to ImpediMed.
ImpediMed Chief Medical Officer, Steven L. Chen, MD, MBA, one of the study's authors, will present the findings at ASBrS.
According to the American Cancer Society 58% of cancer patients diagnosed with breast cancer, melanoma, or pelvic area cancers are at risk for developing limb lymphedema, and over 80% of breast cancer patients are at risk.

Possible New Hope for Metastatic Cancer Patients: Food and Drug Administration Grants Approval for Clinical Trials For Lamassu's Groundbreaking Cancer Treatment Protocol

Retrieved on:

星期四, 四月 11, 2024

FDA, Cancer, Bangladesh Technical Education Board, Hope, Food, Cleveland Clinic, MD, Peter Anderson, IND, MDM2, Patient, Toxicity, Drug development, SBIR, Growth, Pharmaceutical industry

Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) to proceed in initiate Phase 1/2a clinical trials.

Key Points:

Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) to proceed in initiate Phase 1/2a clinical trials.
The trial will investigate novel therapy SA53-OS, a genetically targeted therapy that targets the MDM2 protein, a key regulator of the tumor suppressor p53 gene.
By selectively activating p53, Lamassu aims to induce tumor cell death and inhibit growth, potentially providing a much-needed breakthrough in targeted cancer therapy.
With SA53-OS patented in 69 countries, successful trials could make a significant impact on the global fight against cancer."